Role of osteocytes in multiple myeloma bone disease

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose of review Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored. Recent findings Multiple myeloma bone disease is characterized by exacerbated bone resorption and the presence of osteolytic lesions that do not heal because of a concomitant reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional profile of osteocytes by upregulating the production of proosteoclastogenic cytokines, stimulating osteoclast formation and activity. Further, patients with active multiple myeloma have elevated circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed by osteocytes in bone. Summary Understanding the contribution of osteocytes to the mechanisms underlying the skeletal consequences of multiple myeloma bone disease has the potential to provide important new therapeutic strategies that specifically target multiple myeloma-osteocyte interactions.

Original languageEnglish
Pages (from-to)407-413
Number of pages7
JournalCurrent Opinion in Supportive and Palliative Care
Volume8
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Osteocytes
Bone Diseases
Multiple Myeloma
Osteogenesis
Bone and Bones
Bone Resorption
Osteoclasts
Cytokines

Keywords

  • Apoptosis
  • Osteoclasts
  • Osteocytes
  • Receptor activator of nuclear factor-kappa b ligand
  • Sclerostin

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)
  • Critical Care and Intensive Care Medicine
  • Oncology(nursing)

Cite this

@article{57874d594b224098afb0b38f6560ea77,
title = "Role of osteocytes in multiple myeloma bone disease",
abstract = "Purpose of review Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored. Recent findings Multiple myeloma bone disease is characterized by exacerbated bone resorption and the presence of osteolytic lesions that do not heal because of a concomitant reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional profile of osteocytes by upregulating the production of proosteoclastogenic cytokines, stimulating osteoclast formation and activity. Further, patients with active multiple myeloma have elevated circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed by osteocytes in bone. Summary Understanding the contribution of osteocytes to the mechanisms underlying the skeletal consequences of multiple myeloma bone disease has the potential to provide important new therapeutic strategies that specifically target multiple myeloma-osteocyte interactions.",
keywords = "Apoptosis, Osteoclasts, Osteocytes, Receptor activator of nuclear factor-kappa b ligand, Sclerostin",
author = "Jesus Delgado-Calle and Teresita Bellido and Roodman, {G. David}",
year = "2014",
doi = "10.1097/SPC.0000000000000090",
language = "English",
volume = "8",
pages = "407--413",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Role of osteocytes in multiple myeloma bone disease

AU - Delgado-Calle, Jesus

AU - Bellido, Teresita

AU - Roodman, G. David

PY - 2014

Y1 - 2014

N2 - Purpose of review Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored. Recent findings Multiple myeloma bone disease is characterized by exacerbated bone resorption and the presence of osteolytic lesions that do not heal because of a concomitant reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional profile of osteocytes by upregulating the production of proosteoclastogenic cytokines, stimulating osteoclast formation and activity. Further, patients with active multiple myeloma have elevated circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed by osteocytes in bone. Summary Understanding the contribution of osteocytes to the mechanisms underlying the skeletal consequences of multiple myeloma bone disease has the potential to provide important new therapeutic strategies that specifically target multiple myeloma-osteocyte interactions.

AB - Purpose of review Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored. Recent findings Multiple myeloma bone disease is characterized by exacerbated bone resorption and the presence of osteolytic lesions that do not heal because of a concomitant reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional profile of osteocytes by upregulating the production of proosteoclastogenic cytokines, stimulating osteoclast formation and activity. Further, patients with active multiple myeloma have elevated circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed by osteocytes in bone. Summary Understanding the contribution of osteocytes to the mechanisms underlying the skeletal consequences of multiple myeloma bone disease has the potential to provide important new therapeutic strategies that specifically target multiple myeloma-osteocyte interactions.

KW - Apoptosis

KW - Osteoclasts

KW - Osteocytes

KW - Receptor activator of nuclear factor-kappa b ligand

KW - Sclerostin

UR - http://www.scopus.com/inward/record.url?scp=84924259117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924259117&partnerID=8YFLogxK

U2 - 10.1097/SPC.0000000000000090

DO - 10.1097/SPC.0000000000000090

M3 - Article

C2 - 25289928

AN - SCOPUS:84924259117

VL - 8

SP - 407

EP - 413

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 4

ER -